Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis-Reference-Cited by-同舟云学术

Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis

Published:2013-06 Issue:6 Volume:73 Page:705-713
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol.

Author:

Khan Omar¹,Rieckmann Peter²,Boyko Alexey³,Selmaj Krzysztof⁴,Zivadinov Robert⁵,

Affiliation:

1. Department of Neurology and Multiple Sclerosis Center; Wayne State University School of Medicine; Detroit; MI

2. Department of Neurology, Bamberg Academic Hospital; University of Erlangen; Bamberg; Germany

3. Department of Neurology and Neurosurgery; Russian National Medical Research University and Moscow Multiple Sclerosis Center; Moscow; Russia

4. Department of Neurology; Medical University of Lodz; Lodz; Poland

5. Department of Neurology, Buffalo Neuroimaging Analysis Center, Department of Neurology; University of Buffalo; Buffalo; NY

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ana.23938/fullpdf

Reference17 articles.

1. Recent insights into the mechanism of action of glatiramer acetate;Kala;J Immunol,2011

2. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond;Aharoni;Autoimmun Rev,2013

3. Glatiramer acetate treatment of multiple sclerosis: an immunological perspective;Racke;J Immunol,2011

4. Multiple sclerosis: geoepidemiology, genetics and the environment;Milo;Autoimmun Rev,2010

5. TEVA Pharmaceuticals USA Copaxone (glatiramer acetate) prescribing information 2009 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020622s057lbl.pdf

Cited by 194 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects;Pharmacological Reports;2024-08-23

2. Race and ethnicity in multiple sclerosis phase 3 clinical trials: A systematic review;Multiple Sclerosis Journal;2024-06-07

3. Tolerability and Acceptance of Switching from Brand to Generic Glatiramer Acetate in Multiple Sclerosis;Journal of Clinical Medicine;2024-05-09

4. Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption;Journal of Neurology;2024-04-14

5. Personalized Use of Disease-Modifying Therapies in Multiple Sclerosis;Pharmaceutics;2024-01-17